Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 24:1416-1418
In metastatic colorectal cancer, KRAS and NRAS genotyping is mandatory before prescription of panitumumab or cetuximab. In order to perform such molecular tests, the French National Cancer Institute has set up a nationwide network of molecular center
Autor:
Nadia Russolillo, Salvatore Siena, Enzo Medico, Michela Buscarino, Federica Di Nicolantonio, Davide Torti, Paolo Massucco, Alberto Bardelli, Alberto Pisacane, Luca Molinaro, Francesco Galimi, Andrea Bertotti, Mauro Risio, Davide Corà, Emanuele Valtorta, Giorgia Migliardi, Francesco Sassi, Claudio Isella, Lorenzo Capussotti, Paolo M. Comoglio, Andrea Muratore, Anna Sapino, Consalvo Petti, Livio Trusolino, Silvia Marsoni, Andrea Sartore-Bianchi, Marcello Gambacorta, Dario Ribero
Publikováno v:
Cancer Discovery; Vol 1
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine.
Autor:
Sander R. Piersma, Henk M.W. Verheul, Thang V. Pham, Livio Trusolino, Tim R.A. Schelfhorst, Connie R. Jimenez, Mariette Labots, Robin Beekhof, Jaco C. Knol, Andrea Bertotti, Nicole C.T. van Grieken
Publikováno v:
Cancer Research. 76:880-880
Introduction: The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has resulted in the clinical use of targeted therapies in the treatmen
Autor:
Tian Zhang, Hope E. Uronis, Andrew J. Armstrong, Rebecca Nagy, Christy Arrowood, Michael A. Morse, Donna Niedzwiecki, Richard B. Lanman, John H. Strickler, AmirAli Talasaz, Herbert Hurwitz, S. Yousuf Zafar, Sherri Haley, Shiao-Wen D. Hsu
Publikováno v:
Molecular Cancer Therapeutics. 14:A52-A52
Background: Several molecular alterations drive acquired resistance to anti-EGFR therapies in pts with KRAS WT mCRC. We designed a clinical trial to identify and treat MET amplification (amp), a well described driver of acquired EGFR resistance. Meth
Autor:
Doron Lipson, Jo-Anne Vergilio, Mark Bailey, James Suh, Rosemary E. Zuna, M. Rowland, Juliann Chmielecki, Philip J. Stephens, Julia A. Elvin, Jeffrey S. Ross, Kathleen N. Moore, Garrett M. Frampton, Vincent A. Miller, Scott McMeekin, Siraj M. Ali
Publikováno v:
Molecular Cancer Therapeutics. 14:A79-A79
Background: Adult granulosa cell tumors account for ∼70% of sex cord stromal tumors of the ovary. Most behave as low-grade malignancies and present as stage I disease. However 20% recur, often after a prolonged time (median time to recurrence 6 yea
Autor:
Iksoo Huh, Hyoki Kim, Si-Hyun Lee, Jaemyun Lyu, Taesung Park, Duhee Bang, Hyojun Han, Yongjun Cha, Sae-Won Han, Jeong Mo Bae, Jae Kyung Won, Gyeong Hoon Kang, Hwang-Phill Kim, Tae-You Kim, Seung-Yong Jeong, Dae-Won Lee, Kyu Joo Park, Hoon Jang
Publikováno v:
Molecular Cancer Therapeutics. 14:A72-A72
Background Although genomic data of CRC continue to accumulate, only limited information on prognostic role of the alterations have been reported. We have analyzed the prognostic impact of the key mutations in CRC using next generation sequencing tec
Autor:
Brian Dougherty, Sarah Ross, William Pao, Paul R. Fisher, Darren Cross, Katie Al-Kadhimi, Cath Eberlein, Daniel Stetson, Zhongwu Lai, Henry Brown, Kenneth S. Thress
Publikováno v:
Clinical Cancer Research. 21:PR05-PR05
First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) are established first line therapies for patients with advanced NSCLC with activating/sensitising mutations in EGFR. Unfortunately, patients ultimately develop disease progression wi
Autor:
Sergio Roman-Roman, Patricia Vrignaud, Ivan Bièche, Manoel Nunes, Sophie Vacher, Louis-Bastien Weiswald, Dominique Bellet, Sophie Richon, Virginie Dangles-Marie, Edouard Turlotte
Publikováno v:
Cancer Research. 73:LB-34
There is a recent increase in the use of patient-derived tumor xenografts (PDX) engrafted into immunodeficient mice as improved preclinical models of patient tumors. An important component in the validation of disease-specific PDXs for clinical relev
Publikováno v:
Cancer Research. 73:2409-2409
Background: KRAS mutation status alone is an imperfect predictor of response to anti-EGFR therapy in CRC, motivating efforts to identify additional molecular traits for RAS pathway activity. This study aimed to build a quantitative readout of RAS pat
Autor:
Roman K. Thomas, Juliann Chmielecki, Kazuhiko Shien, Helen Pan, Katsuyuki Kiura, Cindy L. Vnencak-Jones, Ya-Lun Lin, Hiromasa Yamamoto, Kadoaki Ohashi, Katerina Politi, James Chih-Hsin Yang, Marc Ladanyi, Lu Wang, Shinichi Toyooka, Aoe Keisuke, William Pao, Vincent A. Miller, Lynnette Fernandez, Maria E. Arcila
Publikováno v:
Cancer Research. 72:1897-1897
EGFR mutant lung cancers are highly sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), but in the metastatic setting, acquired drug resistance is inevitable. Second-site EGFR mutations, MET amplification, PIK3CA m